On the occasion of the International Day of Awareness on Myotonic Dystrophy or Steinert’s disease, on September 15, we want to get closer to patients and get to know them better. It is a day of recognition of this disease and those who suffer from it.
It is an exciting time for the community as it is an opportunity to share knowledge and help improve care.
At Arthex Biotech, we have prepared a survey to continue learning about the experiences of the community, and it is that we consider it important to focus the discourse on the patient to find effective treatments that really help.
Arthex Biotech is developing ATX-01, an RNA-based therapy, with a new mechanism of action that has shown promising efficacy in preclinical studies.
We would be very grateful if you could complete the questionnaire. It helps us know you better and know what path we should follow from the investigation of this disease. Remember that in this community, you are not fighting alone!
Access also to the survey on https://forms.gle/ZfD1wYoLTVMCx7bZ7
